Industry News
Nicox Partners with Kowa for U.S. and Global Commercialization of NCX 470

Nicox S.A. has entered into a significant licensing agreement with Kowa Company, Ltd., granting Kowa...

read more
Nicox Partners with Kowa for U.S. and Global Commercialization of NCX 470
July 18, 2025
FDA Accepts Aldeyra’s Resubmitted NDA for Reproxalap in Dry Eye Disease

The U.S. Food and Drug Administration (FDA) has accepted for review Aldeyra Therapeutics’ resubmitte...

read more
FDA Accepts Aldeyra’s Resubmitted NDA for Reproxalap in Dry Eye Disease
July 18, 2025
Harrow Secures Exclusive U.S. Rights to Samsung Bioepis’ Ophthalmology Biosimilars Portfolio

Harrow has announced a definitive commercialization agreement with Samsung Bioepis, granting Harrow ...

read more
Harrow Secures Exclusive U.S. Rights to Samsung Bioepis’ Ophthalmology Biosimilars Portfolio
July 18, 2025
Krystal Biotech Initiates EMERALD-1 Trial: First Patient Dosed in Study of Gene Therapy for Neurotrophic Keratitis

Krystal Biotech has announced the dosing of the first patient in its EMERALD-1 phase 1/2 clinical tr...

read more
Krystal Biotech Initiates EMERALD-1 Trial: First Patient Dosed in Study of Gene Therapy for Neurotrophic Keratitis
July 17, 2025
Sanofi’s Intravitreal Gene Therapy Receives FDA Fast Track Designation for Geographic Atrophy

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAR446597, a one-t...

read more
Sanofi’s Intravitreal Gene Therapy Receives FDA Fast Track Designation for Geographic Atrophy
July 17, 2025
KALA Bio Completes Enrollment in CHASE Phase 2b Trial for Persistent Corneal Epithelial Defect

KALA Bio has announced the completion of enrollment in its CHASE (Corneal Healing After SEcretome th...

read more
KALA Bio Completes Enrollment in CHASE Phase 2b Trial for Persistent Corneal Epithelial Defect
July 16, 2025
Nanoscope Initiates Rolling BLA Submission to FDA for MCO-010, the First Gene-Agnostic Therapy for RP

Nanoscope Therapeutics has announced the initiation of a rolling submission of a biologics license a...

read more
Nanoscope Initiates Rolling BLA Submission to FDA for MCO-010, the First Gene-Agnostic Therapy for RP
July 16, 2025
AAVantgarde Receives FDA Clearance to Advance AAVB-039 for Stargardt Disease into Phase 1/2 Trial

AAVantgarde Bio has announced that the US Food and Drug Administration (FDA) has cleared its investi...

read more
AAVantgarde Receives FDA Clearance to Advance AAVB-039 for Stargardt Disease into Phase 1/2 Trial
July 16, 2025
Belite Bio Completes Enrollment in Global Phase 3 PHOENIX Trial for Geographic Atrophy

Belite Bio, Inc. has announced the completion of enrollment in its pivotal phase 3 PHOENIX trial, a ...

read more
Belite Bio Completes Enrollment in Global Phase 3 PHOENIX Trial for Geographic Atrophy
July 11, 2025
LENZ Therapeutics and Laboratoires Théa Partner to Commercialize LNZ100 for Presbyopia in Canada

LENZ Therapeutics and Laboratoires Théa have announced a license and commercialization agreement und...

read more
LENZ Therapeutics and Laboratoires Théa Partner to Commercialize LNZ100 for Presbyopia in Canada
July 11, 2025
More